<DOC>
	<DOCNO>NCT00992654</DOCNO>
	<brief_summary>The new protocol allow patient enrol A4001050 continuous access Maraviroc treatment interrupt drug commercially available India .</brief_summary>
	<brief_title>A Treatment Access Program To Provide Maraviroc To Eligible Adult Patients Completing A4001050 Study Until Commercial Availability Of Maraviroc ( Celsentri ) In India</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Maraviroc</mesh_term>
	<criteria>Subjects complete A4001050 study continue derive benefit Maraviroc . Subjects willing able comply schedule visit , treatment plan study procedure . Subjects discontinue A4001050 study . Unable provide consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>Open Label Access Program</keyword>
	<keyword>Treatment experience</keyword>
</DOC>